ST 7775
Alternative Names: ST-7775Latest Information Update: 15 Jan 2024
At a glance
- Originator Beijing Scitech-Mq Pharmaceuticals
- Class Antifibrotics; Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatic fibrosis; Pulmonary fibrosis; Renal fibrosis; Solid tumours
Most Recent Events
- 11 Dec 2023 Preclinical trials in Hepatic fibrosis in China (unspecified route) prior to December 2023 (Beijing Scitech-Mq Pharmaceuticals pipeline, December 2023)
- 11 Dec 2023 Preclinical trials in Pulmonary fibrosis in China (unspecified route) prior to December 2023 (Beijing Scitech-Mq Pharmaceuticals pipeline, December 2023)
- 11 Dec 2023 Preclinical trials in Renal fibrosis in China (unspecified route) prior to December 2023 (Beijing Scitech-Mq Pharmaceuticals pipeline, December 2023)